1
|
Martins Pinto M, Ransac S, Mazat JP, Schwartz L, Rigoulet M, Arbault S, Paumard P, Devin A. Mitochondrial quinone redox states as a marker of mitochondrial metabolism. Biochim Biophys Acta Bioenerg 2024; 1865:149033. [PMID: 38368917 DOI: 10.1016/j.bbabio.2024.149033] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 11/29/2023] [Revised: 01/25/2024] [Accepted: 02/09/2024] [Indexed: 02/20/2024]
Abstract
Mitochondrial and thus cellular energetics are highly regulated both thermodynamically and kinetically. Cellular energetics is of prime importance in the regulation of cellular functions since it provides ATP for their accomplishment. However, cellular energetics is not only about ATP production but also about the ability to re-oxidize reduced coenzymes at a proper rate, such that the cellular redox potential remains at a level compatible with enzymatic reactions. However, this parameter is not only difficult to assess due to its dual compartmentation (mitochondrial and cytosolic) but also because it is well known that most NADH in the cells is bound to the enzymes. In this paper, we investigated the potential relevance of mitochondrial quinones redox state as a marker of mitochondrial metabolism and more particularly mitochondrial redox state. We were able to show that Q2 is an appropriate redox mediator to assess the mitochondrial quinone redox states. On isolated mitochondria, the mitochondrial quinone redox states depend on the mitochondrial substrate and the mitochondrial energetic state (phosphorylating or not phosphorylating). Last but not least, we show that the quinones redox state response allows to better understand the Krebs cycle functioning and respiratory substrates oxidation. Taken together, our results suggest that the quinones redox state is an excellent marker of mitochondrial metabolism.
Collapse
Affiliation(s)
- M Martins Pinto
- CNRS, Institut de Biochimie et Génétique Cellulaires, UMR 5095, F-33000 Bordeaux, France; Université de Bordeaux, CNRS, Bordeaux INP, CBMN, UMR 5248, F-33600 Pessac, France; Université de Bordeaux, CNRS, IBGC, UMR 5095, F-33000 Bordeaux, France
| | - S Ransac
- CNRS, Institut de Biochimie et Génétique Cellulaires, UMR 5095, F-33000 Bordeaux, France; Université de Bordeaux, CNRS, IBGC, UMR 5095, F-33000 Bordeaux, France
| | - J P Mazat
- CNRS, Institut de Biochimie et Génétique Cellulaires, UMR 5095, F-33000 Bordeaux, France; Université de Bordeaux, CNRS, IBGC, UMR 5095, F-33000 Bordeaux, France
| | - L Schwartz
- Assistance Publique des Hôpitaux de Paris, France
| | - M Rigoulet
- CNRS, Institut de Biochimie et Génétique Cellulaires, UMR 5095, F-33000 Bordeaux, France; Université de Bordeaux, CNRS, IBGC, UMR 5095, F-33000 Bordeaux, France
| | - S Arbault
- Université de Bordeaux, CNRS, Bordeaux INP, CBMN, UMR 5248, F-33600 Pessac, France
| | - P Paumard
- CNRS, Institut de Biochimie et Génétique Cellulaires, UMR 5095, F-33000 Bordeaux, France; Université de Bordeaux, CNRS, IBGC, UMR 5095, F-33000 Bordeaux, France.
| | - A Devin
- CNRS, Institut de Biochimie et Génétique Cellulaires, UMR 5095, F-33000 Bordeaux, France; Université de Bordeaux, CNRS, IBGC, UMR 5095, F-33000 Bordeaux, France.
| |
Collapse
|
2
|
Hill-Kayser CE, Szalda D, Vachani C, Ginsberg J, Hobbie W, Jacobs L, Hampshire MK, Metz JM, Schwartz L. Patterns of Independence in Adolescent/Young Adult (AYA) Survivors of Childhood Cancer Having Received Radiotherapy (RT). Int J Radiat Oncol Biol Phys 2023; 117:e235. [PMID: 37784935 DOI: 10.1016/j.ijrobp.2023.06.1154] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/04/2023]
Abstract
PURPOSE/OBJECTIVE(S) AYA cancer survivors are at risk for missed care opportunities due to transitions of care and movement towards independence. This study was undertaken to evaluate steps towards independence of AYA survivors voluntarily using a free, Internet-based tool for creation of survivorship care plans (SCP). MATERIALS/METHODS A free, publicly accessible tool, Smart-ALACC (Smart Adult Living after Childhood Cancer) was made available on Oncolink.org. Analysis of convenience sample frame was performed with IRB approval. RESULTS From 12/2017-12/2022, 676 AYA survivors utilized the tool; 55% (372) identified as female. Most (75%, 506) were white, 7% (48) Black, 7% (46) Asian, 6% (42) Hispanic, 5% other/ mixed race. Median age was 20y (R <16 - 46y) and median age at diagnosis was 11 y (R <1y - 21). Most common diagnoses were leukemia (31%, 212), lymphoma (21%, 140), sarcoma (14%, 95), CNS (9%, 54), and neuroblastoma (5%, 37). 311 pts (46%) reported having had RT, most commonly brain (PB) (19%, 60), "mantle" (14%, 43), craniospinal (CSI) (12%, 36), total body irradiation (TBI) (11%, 34), and head/ neck (8%, 26). Most (92%, 619) denied recurrence /secondary malignancy. Users reported being students (64%, 434) or working (24% (163)) full-time (20%) or part-time (4%); 4% (25) were neither. Most reported living with parents (71%, 482), 14% (92) with a partner/ spouse, 7% (46) alone, and 4% (30) with a roommate. Most reported using parental insurance (54%, 368), while 24% (163) had their own private insurance, 7% (49) public, and 2% uninsured. Of 466 users 18+ (466), more were employed (34%, 155, p = 0.04), living separately from parents (40%, 168, p < 0.001), and had independent insurance (52%, 184, p = 0.03). Of users 23+ (244), 141 (57%) were being employed (p < 0.001), 83% (153) living separately from parents (p < 0.001), and 165 (67%) had independent insurance (p < 0.001). Among users age 23+, survivors who had received brain RT (CSI, brain, or TBI) were less likely to live separately parents or with a spouse/ partner (p < 0.001), but equally likely to be employed (Table 1). CONCLUSION AYA survivors choosing to use a SCP tool have diagnoses reflective of diagnostic patterns in pediatric oncology; many have had RT expected to be associated with cognitive and developmental late effects. Despite this, trends towards employment and independence were evident in young adult population compared to adolescent; somewhat less so in survivors having had brain RT. These data suggest that AYA survivors display independence from parents and require population directed survivorship support; future efforts should aim to include a more diverse body of users.
Collapse
Affiliation(s)
- C E Hill-Kayser
- University of Pennsylvania, Department of Radiation Oncology, Philadelphia, PA
| | - D Szalda
- Children's Hospital of Philadelphia, Philadelphia, PA
| | | | - J Ginsberg
- Children's Hospital of Philadelphia, Philadelphia, PA
| | - W Hobbie
- Children's Hospital of Philadelphia, Philadelphia, PA
| | - L Jacobs
- University of Pennsylvania, Department of Internal Medicine, Division of Oncology, Philadelphia, PA
| | | | - J M Metz
- University of Pennsylvania, Department of Radiation Oncology, Philadelphia, PA
| | - L Schwartz
- Children's Hospital of Philadelphia, Philadelphia, PA
| |
Collapse
|
3
|
Schwartz L, Aggarwal K, Grootendorst D, Kotapati S, Fronheiser M, Zhao B, Coronado-Erdmann C, Micsinai-Balan M, Karasarides M, Fojo A, Brown K. 111P Application of radiomics signatures and unidimensional vs volumetric measurement of early tumor growth dynamics (TGD) to predict first-line treatment outcomes in patients with stage IV non-small cell lung cancer (NSCLC). J Thorac Oncol 2023. [DOI: 10.1016/s1556-0864(23)00366-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/04/2023]
|
4
|
White J, Park A, Ryjewski C, Schwartz L, Miller C. A Simple Method To Reduce the Risk of Venous Stent Migration After Endovascular Treatment of Nutcracker Or May-Thurner Syndromes. EJVES Vasc Forum 2023. [DOI: 10.1016/j.ejvsvf.2023.02.037] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/09/2023] Open
|
5
|
Irani A, Von Elten K, Leiferman K, Schwartz L, Irani A. M265 TISSUE EOSINOPHILIA SANS PERIPHERAL BLOOD EOSINOPHILIA: AN UNUSUAL PRESENTATION OF HYPEREOSINOPHILIC SYNDROME (HES)? Ann Allergy Asthma Immunol 2021. [DOI: 10.1016/j.anai.2021.08.382] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
6
|
Wehr M, Lecointre L, Schneider H, Schwartz L, Faller E, Boisramé T, Baldauf JJ, Akladios C. [Outpatient laparoscopic hysterectomy in France: A monocentric randomized trial]. ACTA ACUST UNITED AC 2021; 50:33-39. [PMID: 34509670 DOI: 10.1016/j.gofs.2021.09.003] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/24/2021] [Indexed: 11/24/2022]
Abstract
OBJECTIVE To demonstrate the feasibility of outpatient laparoscopic hysterectomy using the assessment of post-operative quality of life. METHODS A prospective randomized single-center trial was performed in France between 2013 and 2016. A total of 42 patients needed laparoscopic hysterectomy was included. Postoperative quality of life was assessed using the standardized Euroquol questionnaire. Patients filled the score before the operation and then on the 3rd and 30th postoperative day. Secondary outcomes were assessment of postoperative pain, overall quality of life, analgesic use, and anxiety. The patients were randomized into two groups, group A with a conventional hospital stay of 2 to 3 days and group B with a short stay and a discharge the day after the intervention. RESULTS Twenty-one patients were randomized to group A as well as group B. We did not find any significant differences between the two groups in our study either on our primary outcome or in the seconds ones. On day 3, the average of Euroquol score was 0.68 for group A against 0.50 for group B (P=0.05). Likewise, the scores for postoperative pain were similar with 70.6 in group A and 61.8 in group B (P=0.21). The trend was the same for quality of life score or anxiety. CONCLUSION Our study shows the possibility and the safety of outpatient laparoscopic hysterectomy.
Collapse
Affiliation(s)
- M Wehr
- Department of gynecologic surgery, hôpitaux universitaires de Strasbourg, 67091 Strasbourg, France.
| | - L Lecointre
- Department of gynecologic surgery, hôpitaux universitaires de Strasbourg, 67091 Strasbourg, France; I-Cube UMR 7357 laboratoire des sciences de l'ingénieur, de l'informatique et de l'imagerie, université de Strasbourg, 67081 Strasbourg, France; Institut hospitalo-universitaire (IHU) Institute for Minimally Invasive Hybrid Image-Guided Surgery, université de Strasbourg, 67081 Strasbourg, France.
| | - H Schneider
- Centre hospitalier de Saverne, Saverne et Haguenau, France.
| | - L Schwartz
- Centre hospitalier de Haguenau, Saverne et Haguenau, France.
| | - E Faller
- Department of gynecologic surgery, hôpitaux universitaires de Strasbourg, 67091 Strasbourg, France.
| | - T Boisramé
- Department of gynecologic surgery, hôpitaux universitaires de Strasbourg, 67091 Strasbourg, France.
| | - J-J Baldauf
- Department of gynecologic surgery, hôpitaux universitaires de Strasbourg, 67091 Strasbourg, France.
| | - C Akladios
- Department of gynecologic surgery, hôpitaux universitaires de Strasbourg, 67091 Strasbourg, France.
| |
Collapse
|
7
|
Kistler P, Chieng D, Tonchev I, Sugumar H, McLellan A, Prabhu S, Voskoboinik A, Schwartz L, Parameswaran R, Anderson R, Al-Kaisey A, Ling L, Lee G, Kalman J. P-wave Morphology in Focal Atrial Tachycardia: An Updated 2021 Algorithm to Predict Site of Origin. Heart Lung Circ 2021. [DOI: 10.1016/j.hlc.2021.06.158] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
8
|
Bajaj B, Irani A, Schwartz L, Leiferman K. M248 EOSINOPHIL FOOTPRINTS IN CARDIAC TISSUE IN A PATIENT WITH HYPEREOSINOPHILIC SYNDROME (HES). Ann Allergy Asthma Immunol 2020. [DOI: 10.1016/j.anai.2020.08.276] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
9
|
Bazhenova L, Redman M, Gettinger S, Hirsch F, Mack P, Schwartz L, Gandara D, Bradley J, Stinchcombe T, Leighl N, Ramalingam S, Tavernier S, Minichiello K, Kelly K, Papadimitrakopoulou V, Herbst R. OA04.01 A Phase III Randomized Study of Nivolumab/Ipilimumab vs Nivolumab for Previously Treated Stage IV Squamous Cell Lung Cancer. J Thorac Oncol 2019. [DOI: 10.1016/j.jtho.2019.08.423] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
10
|
Hill-Kayser C, Szalda D, Vachani C, Virgilio L, Psihogios A, O'Hagan B, Cope C, velazquez-Martin B, Hobbie W, Ginsberg J, Daniel L, Barakat L, Fleisher L, Jacobs L, Hampshire M, Metz J, Lunsford N, Sabatino S, Schwartz L. Feasibility and Acceptability of Survivorship Care Plans for Adolescent/ Young Adult Survivors of Childhood Cancer. Int J Radiat Oncol Biol Phys 2019. [DOI: 10.1016/j.ijrobp.2019.06.1214] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
11
|
Kemp CL, Schwartz L, Pace D. INTEREST GROUP COLLABORATIVE SYMPOSIUM: QUALITY CARE FOR PERSONS WITH DEMENTIA IN ASSISTED LIVING AND OTHER LTSS. Innov Aging 2018. [DOI: 10.1093/geroni/igy023.1269] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Affiliation(s)
- C L Kemp
- The Gerontology Institute, Georgia State University, Atlanta, Georgia
| | - L Schwartz
- American Health Care Association/National Center for Assisted Living, Washington, District of Columbia
| | - D Pace
- Alzhiemer’s Association, Alexandria, Virginia
| |
Collapse
|
12
|
Alnajar M, wahoush O, Schwartz L, De Laat S, Hunt M, Khater W, Abu-Siam I, Alnajar M. 6.10-P30Researching palliative care in humanitarian crises: Jordan case study. Eur J Public Health 2018. [DOI: 10.1093/eurpub/cky048.234] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Affiliation(s)
| | | | | | | | - M Hunt
- McGill University, Montreal, Canada
| | - W Khater
- Jordan University of Science and Technology, Jordan
| | | | - M Alnajar
- School of Nursing- The University of Jordan, Jordan
| |
Collapse
|
13
|
Schwartz L, Bezanson K, Wahoush O, Nouvet E, de Laat S, Bernard C, Redwood-Campbell L, Elit L, Upshur R, Chenier A, Hunt M. 6.10-P26“There is no time for these patients”: ethics, obstacles and palliative care in humanitarian settings. Eur J Public Health 2018. [DOI: 10.1093/eurpub/cky048.230] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Affiliation(s)
| | | | | | - E Nouvet
- University of Western Ontario, Canada
| | | | | | | | - L Elit
- McMaster University, Canada
| | | | | | - M Hunt
- McGill University, Toronto, Canada
| |
Collapse
|
14
|
Daniel LC, Wang M, Srivastava D, Schwartz L, Brinkman T, Edelstein K, Mulrooney D, Zhou E, Howell R, Gibson T, Leisenring W, Armstrong GT, Krull K. 0863 Sleep Behaviors And Patterns In Adult Survivors Of Childhood Cancers: A Report From The Childhood Cancer Survivor Study (CCSS). Sleep 2018. [DOI: 10.1093/sleep/zsy061.862] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Affiliation(s)
| | - M Wang
- St. Jude Children’s Research Hospital, Memphis, TN
| | - D Srivastava
- St. Jude Children’s Research Hospital, Memphis, TN
| | - L Schwartz
- The Children’s Hospital of Philadelphia, Philadelphia, PA
| | - T Brinkman
- St. Jude Children’s Research Hospital, Memphis, TN
| | - K Edelstein
- Princess Margaret Cancer Center, Toronto, ON, CANADA
| | - D Mulrooney
- St. Jude Children’s Research Hospital, Memphis, TN
| | - E Zhou
- Havard Medical School, Boston, MA
| | - R Howell
- MD Anderston Cancer Center, Houston, TX
| | - T Gibson
- St. Jude Children’s Research Hospital, Memphis, TN
| | - W Leisenring
- Fred Hutchinson Cancer Research Center, Seattle, WA
| | | | - K Krull
- St. Jude Children’s Research Hospital, Memphis, TN
| |
Collapse
|
15
|
Affiliation(s)
- N.G. Castle
- University of Pittsburgh, Allison Park, Pennsylvania,
| | | |
Collapse
|
16
|
Schwartz L, Carder P. QUALITY IN ASSISTED LIVING: INTERNATIONAL AND CULTURAL FINDINGS AND RECOMMENDATIONS. Innov Aging 2017. [DOI: 10.1093/geroni/igx004.2583] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Affiliation(s)
- L. Schwartz
- American Health Care Association/National Center for Assisted Living
| | | |
Collapse
|
17
|
|
18
|
Dummer R, Sondak V, Grichnik J, Schwartz L, Guminski A, Gutzmer R, Yi T, Trylesinski A, Sellami D, Migden M. 3347 BOLT 18-month analysis: efficacy and safety of sonidegib in patients with locally advanced basal cell carcinoma (laBCC) and evaluation of tumor response using 2 sets of composite assessment criteria. Eur J Cancer 2015. [DOI: 10.1016/s0959-8049(16)31865-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
19
|
Garbin O, Schwartz L. Nouvelle technique en hystéroscopie : les morcellateurs hystéroscopiques. ACTA ACUST UNITED AC 2014; 42:872-6. [DOI: 10.1016/j.gyobfe.2014.10.002] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/11/2014] [Accepted: 09/12/2014] [Indexed: 11/26/2022]
|
20
|
Burnett B, Schwartz L, Tobias JD. Anaesthesia with dexmedetomidine and remifentanil in a child with mitochondrial myopathy. Southern African Journal of Anaesthesia and Analgesia 2014. [DOI: 10.1080/22201173.2011.10872788] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
Affiliation(s)
- B Burnett
- Department of Anesthesiology, Nationwide Children's Hospital and The Ohio State University, Columbus, Ohio
| | - L Schwartz
- Department of Anesthesiology, Nationwide Children's Hospital and The Ohio State University, Columbus, Ohio
| | - JD Tobias
- Department of Anesthesiology and Pain Medicine, Nationwide Children's Hospital
- The Ohio State University, Columbus, Ohio
| |
Collapse
|
21
|
Zhao B, Tan Y, Tsai W, Lu L, Schwartz L, Lu Z, So J, Goldman J. TU-A-12A-07: CT-Based Biomarkers to Characterize Lung Lesion: Effects of CT Dose, Slice Thickness and Reconstruction Algorithm Based Upon a Phantom Study. Med Phys 2014. [DOI: 10.1118/1.4889253] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022] Open
|
22
|
Lalezari S, Martinowitz U, Windyga J, Enriquez MM, Delesen H, Schwartz L, Scharrer I. Correlation between endogenous VWF:Ag and PK parameters and bleeding frequency in severe haemophilia A subjects during three-times-weekly prophylaxis with rFVIII-FS. Haemophilia 2013; 20:e15-22. [PMID: 24252058 PMCID: PMC4233978 DOI: 10.1111/hae.12294] [Citation(s) in RCA: 29] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 10/07/2013] [Indexed: 11/30/2022]
Abstract
Patients with severe haemophilia A experience frequent and spontaneous bleeding, causing debilitating damage to joints and decreasing quality of life. Prophylaxis with factor VIII (FVIII) reduces joint damage if initiated early. Circulating FVIII levels may be influenced by endogenous von Willebrand factor (VWF), a chaperone protein that binds and stabilizes FVIII. The aim of this study was to determine whether endogenous VWF antigen (VWF:Ag) levels are correlated with FVIII pharmacokinetic (PK) parameters and clinical outcomes in patients with severe haemophilia A. Previously treated, non-inhibitor patients in a multinational, randomized, double-blind, Ph II study received prophylaxis with once-weekly BAY 79-4980 (35 IU kg−1) or thrice-weekly recombinant sucrose-formulated FVIII (rFVIII-FS; 25 IU kg−1). PK parameters were evaluated at weeks 1 and 26. The number of bleeds per patient during the study was captured as part of the core efficacy endpoint. Spearman rank correlations assessed relationships of VWF:Ag levels with patient age, PK and annualized bleeding rate. Of 131 study patients (aged 13−64 years; BAY 79-4980, n = 63; rFVIII-FS, n = 68), 27 (21%; n = 15 and 12 respectively) were evaluable for PK assessment. Baseline VWF:Ag levels correlated with patient age (P < 0.0001). There was no significant difference in PK results between treatments; thus, PK parameters and VWF levels of all patients were analysed together. AUCnorm and T1/2 significantly increased with increased VWF:Ag (P < 0.001); clearance significantly decreased with increased VWF:Ag (P = 0.002). Annualized bleeding rate in patients treated with 3× per week rFVIII-FS significantly correlated with VWF:Ag and age (P = 0.038 and 0.021 respectively). PK parameters as well as the clinical outcome significantly correlated with endogenous VWF:Ag. The improved clinical outcome in subjects with high VWF:Ag levels may be explained by VWF:Ag influence on FVIII PK.
Collapse
Affiliation(s)
- S Lalezari
- National Hemophilia Center, Chaim Sheba Medical Center, Tel Hashomer, Israel
| | | | | | | | | | | | | |
Collapse
|
23
|
Tan Y, Weinfeld J, Lee S, So J, Schwartz L, Lu Z, Zhao B. SU-E-CAMPUS-J-02: Exploring Appropriate CT Acquisition Parameters for Measuring Tumor Volumes in Response Assessment Using An Anthropomorphic Thorax Phantom. Med Phys 2013. [DOI: 10.1118/1.4815174] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022] Open
|
24
|
Persigehl T, Mojahed H, Mui L, Siegel A, Laue H, Heindel W, Arias-Mendoza F, Schwartz L. Multi-parametrisches MR-Protokoll zur morphologischen und funktionellen Evaluierung von Hepatozellulären Karzinomen (HCC). ROFO-FORTSCHR RONTG 2013. [DOI: 10.1055/s-0033-1346348] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
25
|
Stahlhut L, Bunck A, Tan Y, Franke M, Höink A, Guo X, Maintz D, Schwartz L, Zhao B, Persigehl T. Evaluierung der Inter-/Intrareader Reproduzierbarkeit unterschiedlich erfahrener Untersucher beim Therapiemonitoring von Pleuramesotheliomen mittels mRECIST, RECIST 1.0, RECIST 1.1 und WHO Kriterien. ROFO-FORTSCHR RONTG 2013. [DOI: 10.1055/s-0033-1346330] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
26
|
Bradbury AR, Patrick-Miller L, Egleston B, Schwartz L, Tuchman L, Moore C, Rauch P, Sands C, Shorter R, Rowan B, Malhotra S, van Decker S, Schmidheiser H, Sicilia P, Bealin L, Daly M. Abstract P6-08-01: Perceptions of breast cancer risk, psychological adjustment and behaviors in adolescent girls at high-risk and population-risk for breast cancer. Cancer Res 2012. [DOI: 10.1158/0008-5472.sabcs12-p6-08-01] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
BACKGROUND: Preliminary evidence suggests that many girls from breast cancer (BC) families are aware of their increased risk for BC. How this awareness impacts their psychosocial adjustment and health behaviors remains unknown.
METHODS: 11–19 YO girls at high-risk (HR) or population-risk (PR) for BC completed self-administered quantitative surveys informed by the Self-Regulation Theory of Health Behavior. Girls with a first or second-degree relative with BC were classified as HR. For hypothesis testing, we used simple linear and logistic regressions. To account for correlation of responses within families, we used robust (cluster-corrected) standard errors or Generalized Estimating Equations.
RESULTS: 47 PR and 89 HR girls have completed surveys. Age did not differ between groups (Mage = 15.6; SD=2.4). 30% of HR girls have a mother with BC. 67% of HR girls vs. 30% of PR girls reported self-perceived risk for adult BC to be “higher than other girls my age,” (p = <0.01, Table 1).
Perceived risk was associated with an increasing number of first and second-degree relatives with BC (p = 0.002) and older age (p = 0.01). There was no evidence that the relationship between perceived risk and age was moderated by risk status (p = 0.740 for interaction terms). The majority of both HR and PR girls reported that there are things women and girls their age can do to prevent BC. (table 1) Perceived controllability of BC did not differ significantly by age or risk status. HR girls reported higher general anxiety (p = 0.07), but not depression than PR girls. HR girls more frequently reported tobacco use than PR girls (p = 0.05). HR girls also reported greater alcohol use, more frequent performance of self-breast exams and less frequent physical activity than PR girls, although these differences were not significant.
CONCLUSION: Girls from BC families are more likely to perceive themselves to be at increased risk for BC, to experience more general anxiety, and to have engaged more frequently in risk behaviors, particularly tobacco use. The majority of girls perceive BC to be preventable both for women in general and for themselves, suggesting a potential “teachable moment” among adolescents that might be sustainable across the lifespan. Further research evaluating knowledge and perceptions of breast cancer risk throughout adolescent development and differences among subgroups could inform strategies to optimize adolescent psychosocial responses to hereditary cancer risk and promote preventive health behaviors among both HR and PR girls.
Citation Information: Cancer Res 2012;72(24 Suppl):Abstract nr P6-08-01.
Collapse
Affiliation(s)
- AR Bradbury
- University of Pennsylvania, Philadelphia, PA; University of Chicago, IL; Fox Chase Cancer Center, Philadelphia, PA; The Children's Hospital of Philadelphia, Philadelphia, PA; Children's National Medical Center, Washington, DC; Massachusetts General Hospital, Boston, MA
| | - L Patrick-Miller
- University of Pennsylvania, Philadelphia, PA; University of Chicago, IL; Fox Chase Cancer Center, Philadelphia, PA; The Children's Hospital of Philadelphia, Philadelphia, PA; Children's National Medical Center, Washington, DC; Massachusetts General Hospital, Boston, MA
| | - B Egleston
- University of Pennsylvania, Philadelphia, PA; University of Chicago, IL; Fox Chase Cancer Center, Philadelphia, PA; The Children's Hospital of Philadelphia, Philadelphia, PA; Children's National Medical Center, Washington, DC; Massachusetts General Hospital, Boston, MA
| | - L Schwartz
- University of Pennsylvania, Philadelphia, PA; University of Chicago, IL; Fox Chase Cancer Center, Philadelphia, PA; The Children's Hospital of Philadelphia, Philadelphia, PA; Children's National Medical Center, Washington, DC; Massachusetts General Hospital, Boston, MA
| | - L Tuchman
- University of Pennsylvania, Philadelphia, PA; University of Chicago, IL; Fox Chase Cancer Center, Philadelphia, PA; The Children's Hospital of Philadelphia, Philadelphia, PA; Children's National Medical Center, Washington, DC; Massachusetts General Hospital, Boston, MA
| | - C Moore
- University of Pennsylvania, Philadelphia, PA; University of Chicago, IL; Fox Chase Cancer Center, Philadelphia, PA; The Children's Hospital of Philadelphia, Philadelphia, PA; Children's National Medical Center, Washington, DC; Massachusetts General Hospital, Boston, MA
| | - P Rauch
- University of Pennsylvania, Philadelphia, PA; University of Chicago, IL; Fox Chase Cancer Center, Philadelphia, PA; The Children's Hospital of Philadelphia, Philadelphia, PA; Children's National Medical Center, Washington, DC; Massachusetts General Hospital, Boston, MA
| | - C Sands
- University of Pennsylvania, Philadelphia, PA; University of Chicago, IL; Fox Chase Cancer Center, Philadelphia, PA; The Children's Hospital of Philadelphia, Philadelphia, PA; Children's National Medical Center, Washington, DC; Massachusetts General Hospital, Boston, MA
| | - R Shorter
- University of Pennsylvania, Philadelphia, PA; University of Chicago, IL; Fox Chase Cancer Center, Philadelphia, PA; The Children's Hospital of Philadelphia, Philadelphia, PA; Children's National Medical Center, Washington, DC; Massachusetts General Hospital, Boston, MA
| | - B Rowan
- University of Pennsylvania, Philadelphia, PA; University of Chicago, IL; Fox Chase Cancer Center, Philadelphia, PA; The Children's Hospital of Philadelphia, Philadelphia, PA; Children's National Medical Center, Washington, DC; Massachusetts General Hospital, Boston, MA
| | - S Malhotra
- University of Pennsylvania, Philadelphia, PA; University of Chicago, IL; Fox Chase Cancer Center, Philadelphia, PA; The Children's Hospital of Philadelphia, Philadelphia, PA; Children's National Medical Center, Washington, DC; Massachusetts General Hospital, Boston, MA
| | - S van Decker
- University of Pennsylvania, Philadelphia, PA; University of Chicago, IL; Fox Chase Cancer Center, Philadelphia, PA; The Children's Hospital of Philadelphia, Philadelphia, PA; Children's National Medical Center, Washington, DC; Massachusetts General Hospital, Boston, MA
| | - H Schmidheiser
- University of Pennsylvania, Philadelphia, PA; University of Chicago, IL; Fox Chase Cancer Center, Philadelphia, PA; The Children's Hospital of Philadelphia, Philadelphia, PA; Children's National Medical Center, Washington, DC; Massachusetts General Hospital, Boston, MA
| | - P Sicilia
- University of Pennsylvania, Philadelphia, PA; University of Chicago, IL; Fox Chase Cancer Center, Philadelphia, PA; The Children's Hospital of Philadelphia, Philadelphia, PA; Children's National Medical Center, Washington, DC; Massachusetts General Hospital, Boston, MA
| | - L Bealin
- University of Pennsylvania, Philadelphia, PA; University of Chicago, IL; Fox Chase Cancer Center, Philadelphia, PA; The Children's Hospital of Philadelphia, Philadelphia, PA; Children's National Medical Center, Washington, DC; Massachusetts General Hospital, Boston, MA
| | - M Daly
- University of Pennsylvania, Philadelphia, PA; University of Chicago, IL; Fox Chase Cancer Center, Philadelphia, PA; The Children's Hospital of Philadelphia, Philadelphia, PA; Children's National Medical Center, Washington, DC; Massachusetts General Hospital, Boston, MA
| |
Collapse
|
27
|
Persigehl T, Mojahed H, Mui L, Siegel A, Laue H, Heindel W, Arias-Mendoza F, Schwartz L. Klinische Evaluierung der diagnostischen Qualität eines multi-parametrischen MR-Protokolls zum Staging und Therapiemonitoring von Hepatozellulären Karzinomen (HCC). ROFO-FORTSCHR RONTG 2012. [DOI: 10.1055/s-0032-1329759] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
28
|
Abou-Alfa G, Zhao B, Chou J, Ma J, Capanu M, Koga M, Lee R, Othomo T, Germino J, Schwartz L. 318 Effects of Radiologic Tumor Response of Anti-Glypican-3 GC33 and Multi Tyrosine Kinases Inhibitor Sorafenib in Hepatocellular Carcinoma. Eur J Cancer 2012. [DOI: 10.1016/s0959-8049(12)72116-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
29
|
Schwartz L, Hunt M, Sinding C, Elit L, Redwood-Campbell L, Adelson N, de Laat S. Models for Humanitarian Health Care Ethics. Public Health Ethics 2012. [DOI: 10.1093/phe/phs005] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
30
|
Hunt MR, Schwartz L. Editorial: Introduction to Symposium on Ethics and Humanitarian Healthcare Policy and Practice. Public Health Ethics 2012. [DOI: 10.1093/phe/phs006] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
31
|
Hunt MR, Schwartz L, Elit L. Experience of Ethics Training and Support for Health Care Professionals in International Aid Work. Public Health Ethics 2011. [DOI: 10.1093/phe/phr033] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
32
|
Lacaze L, Le Dem N, Bubenheim M, Tsilividis B, Mezghani J, Schwartz L, Francois A, Ertaud JY, Bagot d'Arc M, Scotté M. Tensile strength of biological fibrin sealants: a comparative study. J Surg Res 2011; 176:455-9. [PMID: 22341344 DOI: 10.1016/j.jss.2011.11.1017] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/27/2011] [Revised: 11/03/2011] [Accepted: 11/18/2011] [Indexed: 01/23/2023]
Abstract
BACKGROUND Fibrin sealants are commonly used in liver surgery, although their effectiveness in routine clinical practice remains controversial. Individual sealant characteristics are based on hemostatic effects and adhesion properties that can be experimentally measured using the 'rat skin test' or the 'pig skin test'. This study used a more relevant and realistic experimental canine model to compare the differences in the adhesive properties of four fibrin sealants in hepatectomy: Tisseel/Tissucol, Tachosil, Quixil, and Beriplast. MATERIALS AND METHODS A partial hepatectomy was performed in beagle dogs under general anesthesia to obtain liver cross-sections. Fibrin sealants were allocated to dog livers using a Youden square design. The tensile strength measurement was performed using a traction system to measure the rupture stress point of a small wooden cylinder bonded to the liver cross-section. RESULTS Significantly greater adhesion properties were observed with Tisseel/Tissucol compared with Quixil or Beriplast (P = 0.002 and 0.001, respectively). Similarly, Tachosil demonstrated significantly greater adhesive properties compared with Beriplast (P = 0.009) or Quixil (P = 0.014). No significant differences were observed between Tisseel/Tissucol and Tachosil or between Beriplast and Quixil. CONCLUSIONS The results of this comparative study demonstrate that different fibrin sealants exhibit different adhesive properties. Tisseel/Tissucol and Tachosil provided greatest adhesion to liver cross-section in our canine model of hepatectomy. These results may enable the optimal choice of fibrin sealants for this procedure in clinical practice.
Collapse
Affiliation(s)
- Laurence Lacaze
- Digestive Surgery Department, Rouen University Hospital, Rouen, France
| | | | | | | | | | | | | | | | | | | |
Collapse
|
33
|
Zhao B, Tan Y, Li Y, Guo P, Schwartz L. SU-E-T-40: Exploring the Reproducibility of Tumor Volumes Measured by Radiologist, Computer-Aided Radiologist and Computer Alone. Med Phys 2011. [DOI: 10.1118/1.3611991] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022] Open
|
34
|
Prinzmetal M, Corday E, Bergman HC, Schwartz L, Spritzler RJ. Radiocardiography: A New Method for Studying the Blood Flow Through the Chambers of the Heart in Human Beings. Science 2010; 108:340-1. [PMID: 17748042 DOI: 10.1126/science.108.2804.340] [Citation(s) in RCA: 79] [Impact Index Per Article: 5.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/02/2022]
|
35
|
Sinding C, Schwartz L, Hunt M, Redwood-Campbell L, Elit L, Ranford J. 'Playing God Because you Have to': Health Professionals' Narratives of Rationing Care in Humanitarian and Development Work. Public Health Ethics 2010. [DOI: 10.1093/phe/phq015] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
36
|
Collins P, Faradji A, Morfini M, Enriquez MM, Schwartz L. Efficacy and safety of secondary prophylactic vs. on-demand sucrose-formulated recombinant factor VIII treatment in adults with severe hemophilia A: results from a 13-month crossover study. J Thromb Haemost 2010; 8:83-9. [PMID: 19817995 DOI: 10.1111/j.1538-7836.2009.03650.x] [Citation(s) in RCA: 115] [Impact Index Per Article: 8.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
BACKGROUND Hemarthroses in severe hemophilia precipitate physical, psychosocial and financial difficulties. OBJECTIVE To compare the effects of secondary prophylaxis with on-demand sucrose-formulated recombinant factor VIII (rFVIII-FS) therapy in severe hemophilia A. PATIENTS AND METHODS This open-label study included patients aged 30-45 years with factor VIII (FVIII) coagulant activity < 1 IU dL(-1) who were using on-demand FVIII treatment. Patients were treated with rFVIII-FS on demand for 6 months, followed by 7 months prophylaxis (20-40 IU kg(-1), three times per week, with the first month considered a run-in). The primary endpoint was the number of hemarthroses. RESULTS Twenty patients were enrolled (n = 19 completed); the mean age was 36.4 years, and 16 had target joints. The median (25-75%) number of joint bleeds decreased significantly with prophylaxis [0 (0-3)] vs. on-demand [15 (11-26); P < 0.001] therapy. The number of all bleeds was 0 (0-3) vs. 20.5 (14-37; P < 0.001), respectively. Median (range) total Gilbert scores improved after prophylaxis [18 (3-39)] compared with on-demand [25 (4-46)] therapy, predominantly reflecting the improved bleeding score. Median time from last prophylactic infusion to bleed was 2 days; 82.5% of bleeds occurred 2-3 days after the last infusion. Median 48-h and 72-h FVIII trough levels measured during months 10 and 13 were consistently > 6 and > 4 IU dL(-1), respectively. Treatment was well tolerated, and no inhibitor formation was observed. CONCLUSION Secondary prophylaxis with rFVIII-FS significantly reduced the frequency of hemarthroses compared with on-demand therapy in adult patients with severe hemophilia A.
Collapse
Affiliation(s)
- P Collins
- University Hospital of Wales, Cardiff, UK.
| | | | | | | | | |
Collapse
|
37
|
Carroll S, Strachan P, Schwartz L, Arthur H. SP46 Patients' Decisions about Receiving an ICD for Primary Prevention of Sudden Cardiac Death - Information Gathering in Patient Waiting Rooms from “Armchair Expert” ICD Veterans. Eur J Cardiovasc Nurs 2009. [DOI: 10.1016/s1474-5151(09)60157-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
38
|
Ford R, Schwartz L, Dancey J, Dodd LE, Eisenhauer EA, Gwyther S, Rubinstein L, Sargent D, Shankar L, Therasse P, Verweij J. Lessons learned from independent central review. Eur J Cancer 2009; 45:268-74. [PMID: 19101138 DOI: 10.1016/j.ejca.2008.10.031] [Citation(s) in RCA: 86] [Impact Index Per Article: 5.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/17/2008] [Accepted: 10/29/2008] [Indexed: 11/19/2022]
Abstract
Independent central review (ICR) is advocated by regulatory authorities as a means of independent verification of clinical trial end-points dependent on medical imaging, when the data from the trials may be submitted for licensing applications [Food and Drug Administration. United States food and drug administration guidance for industry: clinical trial endpoints for the approval of cancer drugs and biologics. Rockville, MD: US Department of Health and Human Services; 2007; Committee for Medicinal Products for Human Use. European Medicines Agency Committee for Medicinal Products for Human Use (CHMP) guideline on the evaluation of anticancer medicinal products in man. London, UK: European Medicines Agency; 2006; United States Food and Drug Administration Center for Drug Evaluation and Research. Approval package for application number NDA 21-492 (oxaliplatin). Rockville, MD: US Department of Health and Human Services; 2002; United States Food and Drug Administration Center for Drug Evaluation and Research. Approval package for application number NDA 21-923 (sorafenib tosylate). Rockville, MD: US Department of Health and Human Services; 2005; United States Food and Drug Administration Center for Drug Evaluation and Research. Approval package for application number NDA 22-065 (ixabepilone). Rockville, MD: US Department of Health and Human Services; 2007; United States Food and Drug Administration Center for Drug Evaluation and Research. Approval package for application number NDA 22-059 (lapatinib ditosylate). Rockville, MD: US Department of Health and Human Services; 2007; United States Food and Drug Administration Center for Biologics Evaluation and Research. Approval package for BLA numbers 97-0260 and BLA Number 97-0244 (rituximab). Rockville, MD: US Department of Health and Human Services; 1997; United States Food and Drug Administration. FDA clinical review of BLA 98-0369 (Herceptin((R)) trastuzumab (rhuMAb HER2)). FDA Center for Biologics Evaluation and Research; 1998; United States Food and Drug Administration. FDA Briefing Document Oncology Drugs Advisory Committee meeting NDA 21801 (satraplatin). Rockville, MD: US Department of Health and Human Services; 2007; Thomas ES, Gomez HL, Li RK, et al. Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment. JCO 2007(November):5210-7]. In addition, clinical trial sponsors have used ICR in Phase I-II studies to assist in critical pathway decisions including in-licensing of compounds [Cannistra SA, Matulonis UA, Penson RT, et al. Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer. JCO 2007(November):5180-6; Perez EA, Lerzo G, Pivot X, et al. Efficacy and safety of ixabepilone (BMS-247550) in a phase II study of patients with advanced breast cancer resistant to an anthracycline, a taxane, and capecitabine. JCO 2007(August):3407-14; Vermorken JB, Trigo J, Hitt R, et al. Open-label, uncontrolled, multicenter phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum-based therapy. JCO 2007(June):2171-7; Ghassan KA, Schwartz L, Ricci S, et al. Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. JCO 2006(September):4293-300; Boué F, Gabarre J, GaBarre J, et al. Phase II trial of CHOP plus rituximab in patients with HIV-associated non-Hodgkin's lymphoma. JCO 2006(September):4123-8; Chen HX, Mooney M, Boron M, et al. Phase II multicenter trial of bevacizumab plus fluorouracil and leucovorin in patients with advanced refractory colorectal cancer: an NCI Treatment Referral Center Trial TRC-0301. JCO 2006(July):3354-60; Ratain MJ, Eisen T, Stadler WM, et al. Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. JCO 2006(June):2502-12; Jaffer AA, Lee FC, Singh DA, et al. Multicenter phase II trial of S-1 plus cisplatin in patients with untreated advanced gastric or gastroesophageal junction adenocarcinoma. JCO 2006(February):663-7; Bouché O, Raoul JL, Bonnetain F, et al. Randomized multicenter phase II trial of a biweekly regimen of fluorouracil and leucovorin (LV5FU2), LV5FU2 plus cisplatin, or LV5FU2 plus irinotecan in patients with previously untreated metastatic gastric cancer: a Fédération Francophone de Cancérologie Digestive Group Study-FFCD 9803. JCO 2004(November):4319-28]. This article will focus on the definition and purpose of ICR and the issues and lessons learned in the ICR setting primarily in Phase II and III oncology studies. This will include a discussion on discordance between local and central interpretations, consequences of ICR, reader discordance during the ICR, operational considerations and the need for specific imaging requirements as part of the study protocol.
Collapse
Affiliation(s)
- R Ford
- RadPharm, 100 Overlook Center, Princeton, NJ 08540, USA.
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
39
|
Sargent DJ, Rubinstein L, Schwartz L, Dancey JE, Gatsonis C, Dodd LE, Shankar LK. Validation of novel imaging methodologies for use as cancer clinical trial end-points. Eur J Cancer 2008; 45:290-9. [PMID: 19091547 DOI: 10.1016/j.ejca.2008.10.030] [Citation(s) in RCA: 95] [Impact Index Per Article: 5.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/17/2008] [Accepted: 10/29/2008] [Indexed: 11/13/2022]
Abstract
The success or failure of a clinical trial, of any phase, depends critically on the choice of an appropriate primary end-point. In the setting of phases II and III cancer clinical trials, imaging end-points have historically, and continue presently to play a major role in determining therapeutic efficacy. The primary goal of this paper is to discuss the validation of imaging-based markers as end-points for phase II clinical trials of cancer therapy. Specifically, we outline the issues that must be considered, and the criteria that would need to be satisfied, for an imaging end-point to supplement or potentially replace RECIST- defined tumour status as a phase II clinical trial end-point. The key criteria proposed to judge the utility of a new end-point primarily relate to its ability to accurately and reproducibly predict the eventual phase III end-point for treatment effect, which is usually assessed by a difference between two arms on progression free or overall survival, both at the patient and more importantly at the trial level. As will be demonstrated, the level of evidence required to formally and fully validate a new imaging marker as an appropriate end-point for phase II trials is substantial. In many cases, this level of evidence will only become available by conducting a series of coordinated prospectively designed multicentre clinical trials culminating in a formal meta-analysis. We also include a discussion of situations where flexibility may be required, relative to the ideal rigorous evaluation, to accommodate inevitable real-world feasibility constraints.
Collapse
Affiliation(s)
- D J Sargent
- Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA.
| | | | | | | | | | | | | |
Collapse
|
40
|
Eisenhauer E, Therasse P, Bogaerts J, Schwartz L, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubenstein L, Shankar L, Kaplan R, Lacombe D, Verweij J. 32 INVITED New response evaluation criteria in solid tumors: revised RECIST guideline version 1.1. EJC Suppl 2008. [DOI: 10.1016/s1359-6349(08)71964-5] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
|
41
|
Abolhassani M, Wertz X, Pooya M, Chaumet-Riffaud P, Guais A, Schwartz L. Hyperosmolarity causes inflammation through the methylation of protein phosphatase 2A. Inflamm Res 2008; 57:419-29. [DOI: 10.1007/s00011-007-7213-0] [Citation(s) in RCA: 32] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022] Open
|
42
|
Anastasiadou M, Martino AD, Clement D, Liège F, Laude-Boulesteix B, Quang N, Dreyfuss J, Huynh B, Nazac A, Schwartz L, Cohen H. Polarimetric imaging for the diagnosis of cervical cancer. ACTA ACUST UNITED AC 2008. [DOI: 10.1002/pssc.200777805] [Citation(s) in RCA: 47] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
|
43
|
Willison DJ, Emerson C, Szala-Meneok KV, Gibson E, Schwartz L, Weisbaum KM, Fournier F, Brazil K, Coughlin MD. Access to medical records for research purposes: varying perceptions across research ethics boards. J Med Ethics 2008; 34:308-314. [PMID: 18375687 DOI: 10.1136/jme.2006.020032] [Citation(s) in RCA: 27] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/26/2023]
Abstract
INTRODUCTION Variation across research ethics boards (REBs) in conditions placed on access to medical records for research purposes raises concerns around negative impacts on research quality and on human subject protection, including privacy. AIM To study variation in REB consent requirements for retrospective chart review and who may have access to the medical record for data abstraction. METHODS Thirty 90-min face-to-face interviews were conducted with REB chairs and administrators affiliated with faculties of medicine in Canadian universities, using structured questions around a case study with open-ended responses. Interviews were recorded, transcribed and coded manually. RESULTS Fourteen sites (47%) required individual patient consent for the study to proceed as proposed. Three (10%) indicated that their response would depend on how potentially identifying variables would be managed. Eleven sites (38%) did not require consent. Two (7%) suggested a notification and opt-out process. Most stated that consent would be required if identifiable information was being abstracted from the record. Among those not requiring consent, there was substantial variation in recognising that the abstracted information could potentially indirectly re-identify individuals. Concern over access to medical records by an outside individual was also associated with requirement for consent. Eighteen sites (60%) required full committee review. Sixteen (53%) allowed an external research assistant to abstract information from the health record. CONCLUSIONS Large variation was found across sites in the requirement for consent for research involving access to medical records. REBs need training in best practices for protecting privacy and confidentiality in health research. A forum for REB chairs to confidentially share concerns and decisions about specific studies could also reduce variation in decisions.
Collapse
Affiliation(s)
- D J Willison
- Centre for Evaluation of Medicines, St Joseph's Healthcare, McMaster University, 105 Main Street East, P1, Hamilton, ON L8N 1G8, Canada.
| | | | | | | | | | | | | | | | | |
Collapse
|
44
|
Monsky W, Boone J, McGahan J, Badawi R, Buonocore M, Schwartz L. Abstract No. 354 EE: Standardized Advanced Imaging for Tumor Response Assessment in Clinical Trials for Image Guided Interventions. J Vasc Interv Radiol 2008. [DOI: 10.1016/j.jvir.2007.12.408] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022] Open
|
45
|
|
46
|
|
47
|
|
48
|
|
49
|
Schwartz L. S7 Are size-based response criteria appropriate in the era of targeted therapy? EJC Suppl 2007. [DOI: 10.1016/s1359-6349(08)70012-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022] Open
|
50
|
Rizvi NA, Rusch V, Zhao B, Senturk E, Schwartz L, Fury M, Downey R, Rizk N, Krug L, Kris MG. Single agent bevacizumab and bevacizumab in combination with docetaxel and cisplatin as induction therapy for resectable IB-IIIA non-small cell lung cancer. J Clin Oncol 2007. [DOI: 10.1200/jco.2007.25.18_suppl.18045] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
18045 Background: Bevacizumab (Bev) improves response and survival in patients with advanced non-squamous lung cancer with chemotherapy however there are limited data as single agent therapy and in early stage NSCLC. Methods: Patients with resectable stage IB-IIIA NSCLC were eligible. Patients with adenocarcinoma (Cohort 1) received preoperative Bev and docetaxel and cisplatin (DC). Patients with squamous histology, central location or recent hemoptysis received DC induction therapy without Bev (Cohort 2). Cohort 1 received Bev (15 mg/kg) followed by CT 2 weeks later to assess single agent Bev response. Subsequently D (75 mg/m2) and C (75 mg/m2) were given q 3 weeks; an additional 2 cycles of Bev was administered with C2 and C3 of DC (total of 3 preoperative doses of Bev). Cohort 2 received DC alone followed by resection. Both cohorts received adjuvant Bev x 1 year. Study endpoints included response to single agent Bev, downstaging, safety and survival. Results: 19 patients of planned 70 were enrolled (11 Cohort 1 and 8 Cohort 2). On Cohort 1, there were 2 clinical stage IIB and 9 IIIA patients. After single agent Bev (by bimensional measurement), > 10% reduction in tumor size was observed after 2 weeks in 6/11 patients (- 20%, 15%, 16%, 15%, 13% and 20%). After Bev + DC, there were 6/10 (60%) PRs and DC delivery was 96%. 6/10 patient underwent R0 resection; 1 R2 and 2 were unresectable. 1 patient developed hemoptysis preoperatively and 1 patient developed an upper GI bleed post-operatively. There were otherwise no Bev related operative complications observed. 5/9 patients were downstaged by induction treatment. 3 patients received adjuvant bevacizumab to date (median 5.7 cycles). 8 patients were treated on Cohort 2 (3 with stage IB, 1 with IIB and 4 with IIIA). All 8 patients underwent R0 resection. DC delivery was 94% and there were 6/8 PRs. Downstaging was observed in 5/8 patients and 6/8 are receiving adjuvant Bev (median # cycles to date = 6.7). Conclusions: Bev as a single agent demonstrates regression of tumors after 2 weeks. To date, Bev has been safely administered in the neoadjuvant and adjuvant setting. Preoperative chemotherapy is well tolerated with more than 90% full dose drug delivery. The study is ongoing. Supported by Genentech, Inc. [Table: see text]
Collapse
Affiliation(s)
- N. A. Rizvi
- Memor Sloan-Kettering Cancer Ctr, New York, NY
| | - V. Rusch
- Memor Sloan-Kettering Cancer Ctr, New York, NY
| | - B. Zhao
- Memor Sloan-Kettering Cancer Ctr, New York, NY
| | - E. Senturk
- Memor Sloan-Kettering Cancer Ctr, New York, NY
| | - L. Schwartz
- Memor Sloan-Kettering Cancer Ctr, New York, NY
| | - M. Fury
- Memor Sloan-Kettering Cancer Ctr, New York, NY
| | - R. Downey
- Memor Sloan-Kettering Cancer Ctr, New York, NY
| | - N. Rizk
- Memor Sloan-Kettering Cancer Ctr, New York, NY
| | - L. Krug
- Memor Sloan-Kettering Cancer Ctr, New York, NY
| | - M. G. Kris
- Memor Sloan-Kettering Cancer Ctr, New York, NY
| |
Collapse
|